Pages that link to "Q33128832"
Jump to navigation
Jump to search
The following pages link to Effect of sibutramine on weight maintenance after weight loss: a randomised trial (Q33128832):
Displaying 50 items.
- Pharmacotherapies for obesity: past, current, and future therapies (Q21296814) (← links)
- 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. (Q22241393) (← links)
- Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss (Q22241931) (← links)
- Management of Obesity in Adults: European Clinical Practice Guidelines (Q22241943) (← links)
- Long-term effects of weight-reducing drugs in people with hypertension (Q24186054) (← links)
- Long-term effects of weight-reducing drugs in hypertensive patients (Q24200212) (← links)
- Blood pressure increasing effect of sibutramine in obese patients (Q24236098) (← links)
- Long-term effects of weight-reducing drugs in hypertensive patients (Q24239850) (← links)
- Blood pressure increasing effect of sibutramine in obese patients (Q24242723) (← links)
- Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus (Q24245173) (← links)
- Long-term pharmacotherapy for obesity and overweight (Q24247723) (← links)
- Obesity: an overview on its current perspectives and treatment options (Q24792455) (← links)
- Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases (Q28066691) (← links)
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease (Q28273500) (← links)
- Gut hormones and the regulation of energy homeostasis (Q28278826) (← links)
- Drug interventions for the treatment of obesity in children and adolescents (Q28279770) (← links)
- Serotonergic drugs : effects on appetite expression and use for the treatment of obesity (Q28282364) (← links)
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (Q28298603) (← links)
- Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol (Q28344161) (← links)
- Drug treatment for obesity. We need more studies in men at higher risk of coronary events (Q28366537) (← links)
- Cost-effectiveness of pharmacotherapy to reduce obesity (Q28477654) (← links)
- Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials (Q28480564) (← links)
- Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity (Q30399390) (← links)
- Tackling obesity: new therapeutic agents for assisted weight loss (Q30401145) (← links)
- Regulation of appetite to treat obesity (Q30403705) (← links)
- The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data (Q31084624) (← links)
- Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data (Q33195173) (← links)
- The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period (Q33534537) (← links)
- Sleep and rhythm consequences of a genetically induced loss of serotonin. (Q33700725) (← links)
- Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. (Q33787706) (← links)
- Proteome changes in rat plasma in response to sibutramine (Q33825506) (← links)
- Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease. (Q33944878) (← links)
- Facts and principles learned at the 32nd annual Williamsburg Conference on Heart Disease (Q33945130) (← links)
- Mitochondrial uncoupling as a target for drug development for the treatment of obesity (Q33960204) (← links)
- A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study (Q34098873) (← links)
- Allocation concealment in randomised trials: defending against deciphering (Q34116070) (← links)
- The discovery and status of sibutramine as an anti-obesity drug (Q34128195) (← links)
- Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials (Q34173447) (← links)
- Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial (Q34175095) (← links)
- A primary care intervention programme for obesity and coronary heart disease risk factor reduction (Q34225134) (← links)
- Appetite regulation: from the gut to the hypothalamus (Q34290124) (← links)
- Management of obesity in patients with Type 2 diabetes (Q34319377) (← links)
- The neuroendocrinology of childhood obesity (Q34330729) (← links)
- Current and investigational antiobesity agents and obesity therapeutic treatment targets (Q34344786) (← links)
- The neuroendocrinology of obesity (Q34381023) (← links)
- Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials (Q34381196) (← links)
- Health consequences of visceral obesity (Q34454547) (← links)
- Memantine reduces consumption of highly palatable food in a rat model of binge eating (Q34486676) (← links)
- Maintenance of Weight Loss in Adolescents: Current Status and Future Directions (Q34497049) (← links)
- Behavioral and pharmacologic therapies for obesity (Q34543656) (← links)